| 1359 |
National Cancer Institute |
Html |
en |
Cancer Pain (PDQ®)–Health Professional Version |
Expert-reviewed information summary about pain as a complication of cancer or its treatment. Approaches to the management and treatment of cancer-associated pain are discussed. |
| initial pain assessment | 0.567168 |
| baseline pain intensity | 0.558291 |
| treats mild pain | 0.559952 |
| moderate cancer pain | 0.617809 |
| metastatic bone pain | 0.57198 |
| incident cancer pain | 0.559612 |
| acute pain resolves | 0.55829 |
| pain management treatment | 0.568663 |
| ongoing pain management | 0.552517 |
| pain relief ladder | 0.55951 |
| common cancer pain | 0.591113 |
| Neuropathic Pain sections | 0.560808 |
| somatic pain | 0.561569 |
| indicates mild pain | 0.560721 |
| cancer patients | 0.628525 |
| pain intensity | 0.56637 |
| pain management | 0.652391 |
| neuropathic pain | 0.592568 |
| Pain Symptom Manage | 0.699092 |
| cancer pain control | 0.556765 |
| Pain Management Nursing | 0.556277 |
| Pain Physician | 0.561182 |
| pain assessment | 0.597079 |
| Pain Palliat Care | 0.567356 |
| breakthrough cancer pain | 0.563775 |
|
| visceral pain signals | 0.562249 |
| severe cancer pain | 0.582593 |
| PUBMED Abstract | 0.564761 |
| visceral pain | 0.565502 |
| pain assessment toolkit | 0.554382 |
| mild pain | 0.57672 |
| Effective pain management | 0.567467 |
| cancer pain management | 0.592002 |
| pain relief | 0.569023 |
| moderate pain | 0.568137 |
| cancer pain | 0.834476 |
| American Pain Society | 0.557173 |
| pain | 0.954306 |
| acute pain | 0.572092 |
| Abstract | 0.595673 |
| Pain Med | 0.572479 |
| Clin Oncol | 0.552396 |
| severe pain | 0.584777 |
| cancer pain experience | 0.579997 |
| pain scale | 0.566028 |
| pain levels | 0.565618 |
| comprehensive pain assessment | 0.576005 |
| indicates moderate pain | 0.564768 |
| pain receptors | 0.555011 |
|
CLICK HERE |
| 1410 |
National Cancer Institute |
Html |
en |
Endometrial Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease. |
| Surgical Adjuvant Breast | 0.47836 |
| Obstet Gynecol | 0.483376 |
| World Cancer Research | 0.452806 |
| endometrial carcinoma | 0.52954 |
| Engl J Med | 0.456388 |
| American Cancer Society | 0.497798 |
| Br J Cancer | 0.455416 |
| case-control study | 0.441437 |
| Int J Cancer | 0.478131 |
| early-stage breast cancer | 0.461817 |
| intentional weight loss | 0.529248 |
| breast cancer treatment | 0.473891 |
| breast cancer patients | 0.472714 |
| body mass index | 0.470175 |
| endometrial cases | 0.529694 |
| Cancer Causes Control | 0.452081 |
| Natl Cancer Inst | 0.529481 |
| lower endometrial cancer | 0.563354 |
| postmenopausal endometrial cancer | 0.554715 |
| modifiable risk factor | 0.44186 |
| endometrial cancer | 0.948645 |
| invasive breast cancer | 0.472622 |
| Cancer Treat Rep | 0.454232 |
| et al. | 0.498732 |
|
| early breast cancer | 0.472532 |
| tamoxifen-treated breast cancer | 0.462067 |
| nonpolyposis colorectal cancer | 0.457467 |
| endometrial cancer cases | 0.601622 |
| polycystic ovarian syndrome | 0.445837 |
| Cancer Epidemiol Biomarkers | 0.47249 |
| endometrial cancer risk | 0.82277 |
| Cancer Facts | 0.44862 |
| PUBMED Abstract | 0.515106 |
| Nutr Cancer | 0.444116 |
| widespread endometrial cancer | 0.555715 |
| Epidemiol Biomarkers Prev | 0.442397 |
| endometrial cancer incidence | 0.612962 |
| Breast Cancer Prevention | 0.475561 |
| African American women | 0.440785 |
| invasive gynecologic cancer | 0.464853 |
| postmenopausal women | 0.497969 |
| Abstract | 0.52778 |
| breast cancer | 0.526041 |
| adjuvant tamoxifen | 0.441172 |
| physical activity | 0.445711 |
| Breast Cancer Study | 0.467445 |
| breast cancer incidence | 0.479289 |
| National Surgical Adjuvant | 0.475167 |
|
CLICK HERE |
| 1501 |
National Cancer Institute |
Html |
en |
Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma. |
| nodular sclerosis hodgkin | 0.365708 |
| refractory pediatric Hodgkin | 0.351319 |
| refractory Hodgkin | 0.416042 |
| early Hodgkin lymphoma | 0.394054 |
| Hodgkin lymphoma cases | 0.403293 |
| Hodgkin disease-added value | 0.362383 |
| early-stage hodgkin lymphoma | 0.391985 |
| lymphocyte-predominant hodgkin | 0.393688 |
| Radiat Oncol Biol | 0.45608 |
| risk Hodgkin lymphoma | 0.399452 |
| favorable-risk Hodgkin lymphoma | 0.388818 |
| Hodgkin lymphoma histology | 0.402552 |
| pediatric hodgkin lymphoma | 0.479624 |
| German-Austrian Pediatric Hodgkin | 0.419443 |
| classic Hodgkin lymphoma | 0.417403 |
| pediatric Hodgkin disease | 0.379402 |
| high-risk Hodgkin lymphoma | 0.432447 |
| Hodgkin Study Group | 0.371284 |
| sclerosis Hodgkin lymphoma | 0.410888 |
| newly diagnosed Hodgkin | 0.350548 |
| Hodgkin lymphoma treatment | 0.38529 |
| childhood hodgkin lymphoma | 0.384013 |
| familial classical Hodgkin | 0.365775 |
| lymphocyte-predominant Hodgkin lymphoma-experience | 0.349402 |
| childhood hodgkin | 0.486255 |
|
| cancer survivor study | 0.348591 |
| et al. | 0.539517 |
| lymphocyte-rich classical Hodgkin | 0.347809 |
| pediatric hodgkin | 0.578037 |
| intermediate-risk hodgkin lymphoma | 0.423631 |
| advanced Hodgkin lymphoma | 0.416897 |
| refractory Hodgkin lymphoma | 0.395506 |
| PUBMED Abstract | 0.412711 |
| unfavorable pediatric Hodgkin | 0.351719 |
| Hodgkin lymphoma subtype | 0.402744 |
| Lymphocyte-predominant Hodgkin lymphoma | 0.388987 |
| advanced-stage Hodgkin | 0.357413 |
| lymphocyte predominant Hodgkin | 0.374597 |
| Abstract | 0.561102 |
| Clin Oncol | 0.905331 |
| Hodgkin Lymphoma Group | 0.412086 |
| classical Hodgkin lymphoma | 0.427321 |
| Oncol Biol Phys | 0.463188 |
| Hodgkin disease | 0.410937 |
| childhood cancer survivor | 0.348315 |
| unfavorable childhood Hodgkin | 0.356068 |
| hodgkin lymphoma | 0.82441 |
| recurrent Hodgkin lymphoma | 0.392381 |
| predominant Hodgkin lymphoma | 0.394303 |
|
CLICK HERE |
| 1513 |
National Cancer Institute |
Html |
en |
Pancreatic Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of pancreatic cancer. |
| pancreatic carcinoma E6201 | 0.398831 |
| unresectable pancreatic carcinoma | 0.359985 |
| pancreatic malignancy | 0.311753 |
| Engl J Med | 0.337007 |
| Ann Surg | 0.317423 |
| German CONKO-study group | 0.318318 |
| phase iii trial | 0.413157 |
| pancreatic tumors | 0.328586 |
| der Schelling GP | 0.325496 |
| randomized phase | 0.350612 |
| advanced pancreatic adenocarcinoma | 0.470438 |
| randomized trial | 0.376847 |
| patients | 0.470655 |
| investigational new drug | 0.321651 |
| Cooperative Oncology Group | 0.454021 |
| van der Schelling | 0.325555 |
| Moore MJ | 0.343635 |
| fixed-dose rate infusion | 0.313379 |
| pancreatic carcinoma | 0.542646 |
| Ann Oncol | 0.304631 |
| et al. | 0.690156 |
| Best supportive care | 0.315629 |
| study | 0.356854 |
| Expandable metal stents | 0.329142 |
|
| phase ii trial | 0.320548 |
| Hammel et al. | 0.336299 |
| Oncology Group study | 0.328761 |
| Clinical Trials Group | 0.319844 |
| gemcitabine-based induction chemotherapy | 0.328647 |
| National Cancer Institute | 0.337583 |
| den Bosch RP | 0.325608 |
| advanced unresectable pancreatic | 0.366836 |
| metastatic pancreatic cancer | 0.353118 |
| advanced pancreatic cancer | 0.926655 |
| advanced pancreatic carcinoma | 0.404683 |
| unresectable periampullary adenocarcinoma | 0.332936 |
| first-line therapy | 0.306838 |
| van den Bosch | 0.324595 |
| refractory pancreatic cancer | 0.407704 |
| advanced pancreas cancer | 0.35576 |
| Abstract | 0.559395 |
| Clin Oncol | 0.91428 |
| unresectable pancreatic cancer | 0.410252 |
| Canada Clinical Trials | 0.318756 |
| Eastern Cooperative Oncology | 0.46104 |
| drug treatment program | 0.320206 |
| gemcitabine | 0.380059 |
| active chemotherapy regimens | 0.332336 |
|
CLICK HERE |
| 3421 |
National Cancer Institute |
Html |
es |
Antioxidantes y prevención del cáncer |
Antioxidants are substances that may protect cells from the damage caused by unstable molecules known as free radicals. Free radical damage may lead to cancer. Antioxidants interact with and stabilize free radicals and may prevent some of the damage fre |
| nutrition intervention trial | 0.318966 |
| Population Nutrition Intervention | 0.307215 |
| Minerales Antioxidantes | 0.329026 |
| mortality during | 0.312847 |
| skin cancers | 0.309111 |
| Hercberg S | 0.31386 |
| complementos antioxidantes alimenticios | 0.358441 |
| vitamina c | 0.306663 |
| vitamina a | 0.307237 |
| Klein EA | 0.307093 |
| vitamina e | 0.306864 |
| Virtamo J | 0.307865 |
| mortality after | 0.306705 |
| antioxidantes alimenticios | 0.533634 |
| stopping antioxidant vitamins | 0.315828 |
| Internal Medicine | 0.308526 |
| Estados Unidos | 0.333664 |
| antioxidant vitamins | 0.315879 |
| PubMed Abstract | 0.94039 |
| Estudio Demográfico | 0.30775 |
| follow-up after stopping | 0.328778 |
| after stopping antioxidant | 0.315902 |
| skin cancers during | 0.306731 |
| minerales selenio | 0.30885 |
| health beneficial effects | 0.308495 |
|
| randomized controlled | 0.317735 |
| International Journal | 0.310662 |
| health effects | 0.306579 |
| Kristal AR | 0.308705 |
| tomar complementos | 0.660547 |
| Taylor PR | 0.316391 |
| Ezzedine K | 0.307269 |
| general population | 0.307041 |
| supplemental alpha-tocopherol | 0.309241 |
| Kesse-Guyot E | 0.307458 |
| tract cancers | 0.32431 |
| médicos varones | 0.307704 |
| beta carotene | 0.315537 |
| elemento mineral selenio | 0.311109 |
| Cancer Prevention Study | 0.31922 |
| Cancer Prevention Trial | 0.339926 |
| complementos alimenticios | 0.353561 |
| retinol efficacy trial | 0.343648 |
| SU.VI.MAX Study | 0.30914 |
| radicales libres | 0.808852 |
| resultados mixtos | 0.310828 |
| Cancer Institute | 0.352968 |
| New England Journal | 0.317494 |
| Cancer Prevention | 0.362527 |
|
CLICK HERE |
| 3565 |
National Cancer Institute |
Html |
en |
Funding Opportunities |
Find a wide range of funding announcements to support cancer research and training, organized by topic and by funding mechanism. |
| population sciences | 0.493717 |
| promising research areas | 0.56879 |
| research grants | 0.500944 |
| AIDS-related cancer | 0.494918 |
| Cancer Clinical Proteomics | 0.567175 |
| Cancer Complementary | 0.503257 |
| mutant RAS-driven cancers | 0.494379 |
| Cancer Moonshot Blue | 0.59594 |
| Cancer Nanotechnology Research | 0.679363 |
| Cancer program | 0.497422 |
| research community | 0.507936 |
| cancer patients | 0.484719 |
| Research projects | 0.502551 |
| Basic cancer research | 0.680007 |
| Tissue Sample Collection | 0.485994 |
| Reduce Cancer Health | 0.579079 |
| Trans-NIH Research Project | 0.629695 |
| Cancer Health Disparities | 0.713271 |
| surveillance cancer research | 0.666086 |
| basic cancer biology | 0.601818 |
| Cancer Control | 0.538781 |
| biostatistical funding opportunities | 0.51758 |
| Cancer Moonshotâ„ Funding | 0.624526 |
| Ribbon Panel recommendations | 0.479686 |
|
| cancer prevention | 0.563482 |
| Cancer Treatment | 0.485294 |
| epidemiological research | 0.487712 |
| alternative medicine practice | 0.49686 |
| NCI Alliance | 0.464504 |
| Provocative Questions Program | 0.51458 |
| cancer research | 0.973473 |
| treat cancer | 0.476905 |
| recent NCI-supported RFAs | 0.522382 |
| cancer screening procedures | 0.560144 |
| alternative medicine | 0.550525 |
| Analysis Technologies Program | 0.493099 |
| small business | 0.635559 |
| private sector participation | 0.462098 |
| health disparities perspective | 0.521069 |
| RAS Initiative enlists | 0.522897 |
| Outstanding Investigator Award | 0.657445 |
| NCI initiative | 0.486583 |
| Biospecimen Research Branch | 0.595175 |
| Business Innovation Research | 0.566067 |
| Translational Research | 0.497403 |
| Business Technology Transfer | 0.60463 |
| Small Business Technology | 0.604737 |
| research communities | 0.503329 |
|
CLICK HERE |
| 3670 |
National Cancer Institute |
Html |
es |
Estudio TAILORx indica que mujeres con riesgo bajo de recurrencia de cáncer de seno pueden abstenerse de quimioterapia |
Resumen de resultados del estudio TAILORx indica que mujeres con cáncer de seno receptor de hormonas en estadio inicial tienen un riesgo bajo de recurrencia según una prueba de expresión de 21 genes. |
| Assigning Individualized Options | 0.731016 |
| NIC-Clinical Trials Group | 0.677172 |
| Therapy Evaluation Program | 0.674291 |
| quimioterapia adyuvante mejora | 0.979078 |
| doctor joseph sparano | 0.667749 |
| doctora jo anne | 0.660047 |
| llamada puntuación | 0.615517 |
| Estados Unidos | 0.857653 |
| NRG Oncology | 0.56481 |
|
| excelentes resultados | 0.548811 |
| cuáles mujeres | 0.873744 |
| Oncotype DX® | 0.57646 |
| invasivo enfermedad | 0.55814 |
| New England Journal | 0.693093 |
| Clinical Oncology | 0.572538 |
| Nueva Zelanda | 0.530968 |
| estudio tailorx | 0.733998 |
|
CLICK HERE |
| 16838 |
National Cancer Institute |
Html |
en |
University of Texas — Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology |
The focus of the University of Texas MD Anderson Cancer Nanotechnology Training Center is presented here. |
| unique boot camp | 0.665183 |
| lab management skills | 0.648892 |
| Rice University | 0.515834 |
| M.D. | 0.338543 |
| Objectives | 0.334693 |
| MD Anderson | 0.892403 |
| preparation | 0.332958 |
| independent careers | 0.500052 |
| problem | 0.335383 |
| MD Anderson CNTC | 0.66004 |
| Ph.D. | 0.338612 |
| seminar experiences | 0.507875 |
| translational research | 0.966631 |
| academic labs | 0.516268 |
| hands-on coursework | 0.547621 |
| project management | 0.489839 |
| Konstantin Sokolov | 0.587384 |
| future leaders | 0.517794 |
| independent research project | 0.702082 |
| Texas | 0.33468 |
| cancer nanotechnology | 0.891595 |
| translational research projects | 0.795763 |
| training program | 0.532137 |
| multidisciplinary mentorship | 0.538033 |
| post-doctoral training | 0.533942 |
|
| trainees | 0.545607 |
| specific interests | 0.517161 |
| Rebecca | 0.339233 |
| research fellowship grant | 0.692269 |
| multidisciplinary field | 0.50801 |
| Ph.D | 0.333304 |
| cancer translational research | 0.824834 |
| Cancer Management | 0.515303 |
| gap | 0.336671 |
| Principal Investigator | 0.540969 |
| Didactic coursework | 0.550767 |
| completion | 0.335106 |
| Center | 0.334629 |
| MD Anderson Cancer | 0.714625 |
| NCI Nanotechnology Characterization | 0.789772 |
| program faculty mentors | 0.704052 |
| current opportunities | 0.49661 |
| federal resources | 0.494134 |
| new discoveries | 0.52212 |
| Sunil Krishnan | 0.581597 |
| deep understanding | 0.497785 |
| barriers | 0.38628 |
| introductory course | 0.486248 |
| Training Focus | 0.539936 |
|
CLICK HERE |
| 17188 |
National Cancer Institute |
Html |
en |
Fertility Issues in Boys and Men with Cancer |
Fertility issues are common in boys and men getting cancer treatment. Fertility preservation options include sperm banking, testicular shielding, testicular sperm extraction (TESE), and testicular tissue freezing. Support and clinical trials are listed. |
| Sexual Health Issues | 0.508548 |
| cancer treatment | 0.619036 |
| fertility | 0.97146 |
| baseline fertility | 0.628851 |
| family member | 0.464194 |
| cancer therapy | 0.481706 |
| health care team | 0.501109 |
| sperm counts | 0.505642 |
| fertility problems | 0.606189 |
| stem cell transplants | 0.576694 |
| upsetting long-term effects | 0.50079 |
| Sperm banking | 0.500128 |
| Testicular tissue freezing | 0.505046 |
| specific treatment | 0.473076 |
| fertility clinic | 0.610475 |
| professionally led support | 0.49722 |
| sperm-forming cells | 0.50982 |
| reproductive endocrinologist | 0.471953 |
| fertility options | 0.634938 |
| fertility preservation procedures | 0.624595 |
| Testicular sperm extraction | 0.553558 |
| radiation therapy | 0.551741 |
| testicular shielding | 0.519544 |
| sperm cells | 0.508932 |
| Reproductive Medicine | 0.463459 |
|
| cancer treatments | 0.62693 |
| blood stem cell | 0.500463 |
| personal health factors | 0.507399 |
| fertility preservation options | 0.794614 |
| testicular tissue cryopreservation | 0.506676 |
| scatter radiation | 0.468354 |
| male cancer patients | 0.603613 |
| fertility preservation | 0.823931 |
| young male cancer | 0.600402 |
| fertility risks | 0.574477 |
| LIVESTRONG Fertility | 0.586472 |
| rectal cancer | 0.479468 |
| reproductive age | 0.463816 |
| sperm | 0.578609 |
| infertility | 0.495824 |
| doctor | 0.471639 |
| fertility specialist | 0.642942 |
| reproductive medical information | 0.506006 |
| cancer | 0.662671 |
| fertility preservation clinic | 0.634592 |
| fertility preservation discounts | 0.62021 |
| bone marrow transplants | 0.501862 |
| child’s doctor | 0.462088 |
| reproductive organs | 0.558126 |
|
CLICK HERE |
| 17278 |
National Cancer Institute |
Html |
es |
Preparación para cuidar a un enfermo con cancer |
Cuidar a alguien con cáncer avanzado trae desafíos y preocupaciones nuevas. Las personas que cuidan a pacientes deben estar al tanto de muchas cosas y planificar el cuidado de su ser querido. |
| dándoles oportunidad | 0.826428 |
| !No hables asá | 0.973126 |
| Nueva York | 0.867641 |
| principales formas | 0.895606 |
| Oxford University | 0.86575 |
|
| Lynna J | 0.87542 |
| busque consejo | 0.895137 |
| mejores tratamientos | 0.878203 |
| surgen preguntas | 0.922072 |
|
CLICK HERE |